文献速递心律失常心力衰竭与心肌病

心房颤动患者中的心肌病相关基因变异

Cardiomyopathy-Associated Gene Variants in Atrial Fibrillation.
PubMed 文献 · JAMA Cardiol · 2025-01-01

该研究基于UK Biobank与All of Us两个前瞻性队列,评估房颤患者中心肌病相关致病/可能致病变异(CMP-PLP)的患病率及预后意义。结果显示房颤患者CMP-PLP变异患病率约为生物库人群的2倍,早发房颤(<45岁)者约5倍;携带CMP-PLP变异与房颤确诊后新发心肌病/心衰风险增加相关(meta分析HR约1.6,95%CI 1.32-1.90),且独立于临床和多基因风险。

要点

  • 房颤患者CMP-PLP变异患病率约2%,早发房颤者约5%。
  • 房颤患者CMP/HF累积发生率18%,无房颤者3%。
  • 携带CMP-PLP变异与房颤后新发CMP/HF风险增加相关(HR约1.6)。

核心结论

  • 房颤患者中CMP-PLP变异患病率较高,尤其在早发房颤患者中。
  • 携带CMP-PLP变异与房颤确诊后新发心肌病/心衰风险增加相关,独立于临床和多基因风险。
  • 对房颤患者进行基因检测可能识别出心肌病/心衰高风险个体。

研究设计与样本

  • 研究纳入UK Biobank(2006-2023)和All of Us Research Program(2018-2022)两个前瞻性队列。
  • UKB和AllOfUs分别包含393 768和193 232名无血缘关系的基因分型参与者。
  • 评估房颤患者及早发房颤患者中CMP-PLP变异的患病率,并分析其与房颤确诊后新发CMP/HF风险的关联。

主要发现

  • UKB队列中32 281名(8%)参与者有房颤(平均[SD]年龄62[6]岁;20 459名男性[63.4%])。
  • AllOfUs队列中11 901名(6%)参与者有房颤(平均[SD]年龄67[12]岁;6576名男性[55.3%])。
  • 与生物库人群相比,CMP-PLP变异在房颤患者中患病率约为2倍(UKB 2.04%;95%CI 1.89%-2.20%;AllOfUs 2.52%;95%CI 2.25%-2.82%)。
  • 在45岁前发病的房颤患者中,CMP-PLP变异患病率约为5倍(UKB 4.99%;95%CI 3.07%-7.91%;AllOfUs 4.66%;95%CI 3.40%-6.32%)。
  • 房颤患者CMP/HF累积发生率为18%,无房颤患者为3%。

临床怎么用

  • 对房颤患者,尤其早发房颤患者,可考虑基因检测以识别心肌病/心衰高风险个体。
  • 携带CMP-PLP变异的房颤患者需加强心肌病/心衰的监测与随访。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Patients with atrial fibrillation (AF), a common morbid arrhythmia, are more likely to carry rare genetic variants associated with inherited cardiomyopathies. Prior studies on rare pathogenic variants in AF relied on small, hospital referral populations, and knowledge on clinical outcomes remains limited. OBJECTIVE: To evaluate the prevalence and prognostic implications of cardiomyopathy-associated pathogenic or likely pathogenic (CMP-PLP) genetic variants in patients with AF. DESIGN, SETTING, AND PARTICIPANTS: In 2 prospective cohort studies, the prevalence of CMP-PLP variants was assessed in the population of patients with AF and early-onset AF. The association between carrying a CMP-PLP variant and the risk of incident cardiomyopathy or heart failure (CMP/HF) after AF diagnosis was evaluated. Finally, the joint contributions of CMP-PLP variants, clinical risk, and polygenic risk were assessed. Included in this study were 2 large longitudinal cohort studies, the UK Biobank (UKB) (data 2006-2023) and the All of Us Research Program (AllofUs) (2018-2022). The UKB and AllofUs cohorts, respectively, contained 393 768 and 193 232 unrelated genotyped participants. EXPOSURES: CMP-PLP variants. MAIN OUTCOMES AND MEASURES: Prevalence of CMP-PLP variants and risk of incident CMP/HF after AF diagnosis. RESULTS: In the UKB cohort, 32 281 participants (8%) had AF (mean [SD] age, 62 [6] years; 20 459 male [63.4%]). In the AllofUs cohort, 11 901 participants (6%) had AF (mean [SD] age, 67 [12] years; 6576 male [55.3%]). Compared with the biobank populations, CMP-PLP variants were twice as prevalent in patients with AF (UKB, 2.04%; 95% CI, 1.89%-2.20%; AllofUs, 2.52%; 95% CI, 2.25%-2.82%) and 5 times as prevalent in AF with onset before age 45 years (UKB, 4.99%; 95% CI, 3.07%-7.91%; AllofUs, 4.66%; 3.40%-6.32%). Cumulative incidence of CMP/HF was high in patients with AF (18%) compared with patients without AF (3%). Still, among patients with AF without prior CMP/HF (UKB, 20 226; AllofUs, 8330), carrying a CMP-PLP variant was associated with 1.6-fold risk of incident CMP/HF (meta-analysis, 95% CI, 1.32-1.90). Finally, CMP-PLP variants, a polygenic score, and clinical risk factors were independent estimators of CMP/HF. CONCLUSIONS AND RELEVANCE: Results of this cohort study suggest that the prevalence of CMP-PLP variants was substantial in patients with early-onset AF. Patients with AF carrying a CMP-PLP variant had an associated increased risk of future CMP/HF, independent of clinical and polygenic risk. These results indicate that genetic testing in patients with AF may identify individuals at higher risk for developing CMP/HF.

来源:JAMA Cardiol,查看原文。版权归原作者所有。

引用

  1. Wijdeveld LFJM, Ajufo E, Challa SP, et al. Cardiomyopathy-Associated Gene Variants in Atrial Fibrillation. JAMA Cardiol. 2025. PMID: 40305039. doi:10.1001/jamacardio.2025.0460

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。